Strategies for enhancing the oral bioavailability of cannabinoids

References

• Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42:327–360.
   PubMed Web of Science ®Google Scholar
• Bruni N, della PC, Oliaro-Bosso S, et al. Cannabinoid delivery systems for pain and inflammation treatment. Mol. MDPI AG. 2018;23(10):2478.
   Web of Science ®Google Scholar
• Amin MR, Ali DW. Pharmacology of medical cannabis. In: Bukiya AN, editor. Recent advances in cannabinoid physiology and pathology. Cham: Springer International Publishing; 2019. p. 151–165.
   Google Scholar
• Stella B, Baratta F, Della Pepa C, et al. Cannabinoid formulations and delivery systems: current and future options to treat pain. Drugs. Adis. 2021;81:1513–1557.
   Google Scholar
• Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol. 2018;84:2477–2482. Blackwell Publishing Ltd.
   PubMed Web of Science ®Google Scholar
• World Health Organization, and WHO Expert Committee on Drug Dependence. WHO Expert Committee on Drug Dependence: fortieth reportWorld Health Organization; 2018.https://apps.who.int/iris/bitstream/handle/10665/279948/9789241210225-eng.pdf
   Google Scholar
• Zgair A, Lee JB, Wong JCM, et al. Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation. Sci Rep. 2017;7:7.
   PubMedGoogle Scholar
• Taylor L, Gidal B, Blakey G, et al. A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs. 2018;32:1053–1067.
   PubMed Web of Science ®Google Scholar
• Birnbaum AK, Karanam A, Marino SE, et al. Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy. Epilepsia. 2019;60:1586–1592.
   PubMed Web of Science ®Google Scholar
• Franco V, Gershkovich P, Perucca E, et al. The interplay between liver first-pass effect and lymphatic absorption of cannabidiol and its implications for cannabidiol oral formulations. Clin Pharmacokinet. 2020;59:1493–1500.
   PubMed Web of Science ®Google Scholar
• Takano R, Furumoto K, and Shiraki K, et al. Rate-limiting steps of oral absorption for poorly water-soluble drugs in dogs; prediction from a miniscale dissolution test and a physiologically-based computer simulation. Pharm Res. 2008;25:2334–2344.
   PubMed Web of Science ®Google Scholar
• Lewis LD, Fordtran JS. Effect of perfusion rate on absorption, surface area, unstirred water layer thickness, permeability, and intraluminal pressure in the rat ileum in vivo. Gastroenterology. 1975;68:1509–1516.
   PubMed Web of Science ®Google Scholar
• Porter CJH, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6:231–248.
   PubMed Web of Science ®Google Scholar
• Leopoldo M, Nardulli P, Contino M, et al. An updated patent review on P-glycoprotein inhibitors (2011-2018). Expert Opin Ther Pat. 2019;29:455–461.
   PubMed Web of Science ®Google Scholar
• Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005;22:11–23.
   PubMed Web of Science ®Google Scholar
• Benet LZ. The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development. J Pharm Sci. 2013;102:34–42.
   PubMed Web of Science ®Google Scholar
• Pereira de Sousa I, Bernkop-Schnürch A. Pre-systemic metabolism of orally administered drugs and strategies to overcome it. J Control Release. 2014;192:301–309.
   PubMed Web of Science ®Google Scholar
• Zhao M, Ma J, Li M, et al. Cytochrome P450 enzymes and drug metabolism in humans. Int J Mol Sci. 2021;23:22.
   PubMedGoogle Scholar
• Wienkers LC, Heath TG. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov. 2005;4:825–833.
   PubMed Web of Science ®Google Scholar
• Michaels S, Wang MZ. The revised human liver cytochrome P450 “Pie”: absolute protein quantification of CYP4F and CYP3A enzymes using targeted quantitative proteomics. Drug Metab Dispos. 2014;42:1241–1251.
   PubMed Web of Science ®Google Scholar
• Swartz MA. The physiology of the lymphatic system. Adv Drug Deliv Rev. 2001;50:3–20.
   PubMed Web of Science ®Google Scholar
• Gershkovich P, Hoffman A. Uptake of lipophilic drugs by plasma derived isolated chylomicrons: linear correlation with intestinal lymphatic bioavailability. Eur J Pharm Sci. 2005;26:394–404.
   PubMed Web of Science ®Google Scholar
• Amidon GL, Lennernäs H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413–420.
   PubMed Web of Science ®Google Scholar
• Charalabidis A, Sfouni M, Bergström C, et al. The biopharmaceutics classification system (BCS) and the biopharmaceutics drug disposition classification system (BDDCS): beyond guidelines. Int J Pharm Elsevier B.V. 2019;566:264–281.
   PubMed Web of Science ®Google Scholar
• Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci. 2006;29(3–4):278–287.
   PubMed Web of Science ®Google Scholar
• Elgart A, Cherniakov I, Aldouby Y, et al. Improved oral bioavailability of BCS class 2 compounds by self nano-emulsifying drug delivery systems (SNEDDS): the underlying mechanisms for amiodarone and talinolol. Pharm Res. 2013;30:3029–3044.
   PubMed Web of Science ®Google Scholar
• Atsmon J, Cherniakov I, Izgelov D, et al. PTL401, a new formulation based on pro-nano dispersion technology, improves oral cannabinoids bioavailability in healthy volunteers. J Pharm Sci. 2018;107:1423–1429.
   PubMed Web of Science ®Google Scholar
• Knaub K, Sartorius T, and Dharsono T, et al. A novel self-emulsifying drug delivery system (SEDDS) based on Vesisorb® formulation technology improving the oral bioavailability of cannabidiol in healthy subjects. Molecules. 2019;24:2967.
   PubMed Web of Science ®Google Scholar
• Izgelov D, Davidson E, Barasch D, et al. Pharmacokinetic investigation of synthetic cannabidiol oral formulations in healthy volunteers. Eur J Pharm Biopharm. 2020;154:108–115.
   PubMedGoogle Scholar
• de Prá MAA, Vardanega R, Loss CG. Lipid-based formulations to increase cannabidiol bioavailability: in vitro digestion tests, pre-clinical assessment and clinical trial. Int J Pharm. 2021;609:121159.
   PubMedGoogle Scholar
• Atsmon J, Heffetz D, Deutsch L, et al. Single-dose pharmacokinetics of oral cannabidiol following administration of PTL101: a new formulation based on gelatin matrix pellets technology. Clin Pharmacol Drug Dev. 2018;7:751–758.
   PubMed Web of Science ®Google Scholar
• Letendre P, Carley D. Low dose cannabinoid medicaments. 2013.
   Google Scholar
• De Vries JA, Fernandez Cid MV, Heredia Lopez AM, inventors; Echo Pharmaceuticals B.V., assignee. Granulate containing cannabinoid, method for its manufacture and oral dosage unit comprising such granulate patent US20150132400. 2015.
   Google Scholar
• De Vries JA, Fernandez Cid MV, Heredia Lopez AM, et al., inventors; Echo Pharmaceuticals B.V., Neth. assignee. Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders patent WO2015065179A1. 2015.
   Google Scholar
• Pellikaan HC, Vermeulen PS, Jcme B, et al., inventors; Echo pharmaceuticals B.V., assignee. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances, such as cannabinoids patent WO2008033024. 2008.
   Google Scholar
• Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4:1770–1804.
   PubMed Web of Science ®Google Scholar
• Jiang R, Yamaori S, Takeda S, et al. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci. 2011;89:165–170.
   PubMed Web of Science ®Google Scholar
• Izgelov D, Domb AJ, and Hoffman A. The effect of piperine on oral absorption of cannabidiol following acute vs. chronic administration. Eur J Pharm Sci. 2020;148:105313.
   PubMedGoogle Scholar
• Alhamoruni A, Lee A, Wright K, et al. Pharmacological effects of cannabinoids on the Caco-2 cell culture model of intestinal permeability. J Pharmacol Exp Ther. 2010;335:92–102.
   PubMed Web of Science ®Google Scholar
• Cherniakov I, Izgelov D, Domb AJ, et al. The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model. Eur J Pharm Sci. 2017;109:21–30.
   PubMed Web of Science ®Google Scholar
• Cherniakov I, Izgelov D, Barasch D, et al. Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration. J Control Release. 2017;266:1–7.
   PubMed Web of Science ®Google Scholar
• Itin C, Domb AJ, Hoffman A. A meta-opinion: cannabinoids delivered to oral mucosa by a spray for systemic absorption are rather ingested into gastro-intestinal tract: the influences of fed/fasting states. Expert Opin Drug Deliv. 2019;16:1031–1035.
   PubMed Web of Science ®Google Scholar
• Lim SY, Sharan S, Woo S. Model-based analysis of cannabidiol dose-exposure relationship and bioavailability. Pharmacotherapy. 2020;40:291–300.
   PubMed Web of Science ®Google Scholar
• Itin C, Barasch D, and Domb AJ, et al. Prolonged oral transmucosal delivery of highly lipophilic drug cannabidiol. Int J Pharm. 2020;581:119276.
   PubMedGoogle Scholar
• Acquistapace S, Patel L, Patin A, et al. Effects of interesterified lipid design on the short/medium chain fatty acid hydrolysis rate and extent (in vitro). Food Function. 2019;10:4166–4176.
   PubMedGoogle Scholar
• Trevaskis NL, Kaminskas LM, Porter CJH. From sewer to saviour-targeting the lymphatic system to promote drug exposure and activity. Nat Rev Drug Discov. Nature Publishing Group. 2015;14:781–803.
   PubMed Web of Science ®Google Scholar
• Charman WNA, and Stella VJ. Estimating the maximal potential for intestinal lymphatic transport of lipophilic drug molecules. Int J Pharm. 1986;34(1–2):175–178.
   Google Scholar
• Gershkovich P, Hoffman A. Effect of a high-fat meal on absorption and disposition of lipophilic compounds: the importance of degree of association with triglyceride-rich lipoproteins. Eur J Pharm Sci. 2007;32:24–32.
   PubMed Web of Science ®Google Scholar
• Gershkovich P, Fanous J, Qadri B, et al. The role of molecular physicochemical properties and apolipoproteins in association of drugs with triglyceride-rich lipoproteins: in-silico prediction of uptake by chylomicrons. J Pharm Pharmacol. 2009;61:31–39.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Lu Y, and Qi J, et al. An update on oral drug delivery via intestinal lymphatic transport. Acta Pharma Sinica B Chinese Acad Med Sci. 2021;11(8):2449–2468.
   PubMed Web of Science ®Google Scholar
• Caliph SM, Charman WN, Porter CJH. Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. Pharm Assoc J Pharm Sci. 2000;89:1073–1084.
   PubMed Web of Science ®Google Scholar
• Izgelov D, Shmoeli E, and Domb AJ, et al. The effect of medium chain and long chain triglycerides incorporated in self-nano emulsifying drug delivery systems on oral absorption of cannabinoids in rats. Int J Pharm. 2020;580.
   PubMedGoogle Scholar
• Gershkovich P, Qadri B, Yacovan A, et al. Different impacts of intestinal lymphatic transport on the oral bioavailability of structurally similar synthetic lipophilic cannabinoids: dexanabinol and PRS-211,220. Eur J Pharm Sci. 2007;31:298–305.
   PubMed Web of Science ®Google Scholar
• Zgair A, Wong JC, Lee JB, et al. Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines. Am J Transl Res. 2016;8:3448–3459.
   PubMed Web of Science ®Google Scholar
• Feng W, Qin C, Chu YJ, et al. Natural sesame oil is superior to pre-digested lipid formulations and purified triglycerides in promoting the intestinal lymphatic transport and systemic bioavailability of cannabidiol. Eur J Pharm Biopharm. 2021;162:43–49.
   PubMedGoogle Scholar
• Trevaskis NL, Shackleford DM, Charman WN, et al. Intestinal lymphatic transport enhances the post-prandial oral bioavailability of a novel cannabinoid receptor agonist via avoidance of first-pass metabolism. Pharm Res. 2009;26:1486–1495.
   PubMed Web of Science ®Google Scholar
• Murty RB, Murti SB, inventors; Murty pharmaceuticals, inc., assignee. An improved oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein deliveryWO2012033478A1. 2012.
   Google Scholar
• Unpublished data disclosed to authors.
   Google Scholar
• Pertwee RG. Cannabinoids and multiple sclerosis. Mol Neurobiol. 2007;36:45–59.
   PubMed Web of Science ®Google Scholar
• Izgelov D, Freidman M, Hoffman A. Investigation of cannabidiol gastro retentive tablets based on regional absorption of cannabinoids in rats. Eur J Pharm Biopharm. 2020;152:229–235.
   PubMedGoogle Scholar
• Kagan L, Hoffman A. Biopharmaceutical aspects of gastro-retentive dosage forms: the gabapentin paradigm. J Drug Delivery Sci Technol. 2009;19:233–239.
   Google Scholar
• Klausner EA, Lavy E, Friedman M, et al. Expandable gastroretentive dosage forms. J Control Release. 2003;90:143–162.
   PubMed Web of Science ®Google Scholar
• Kagan L, and Hoffman A. Selection of drug candidates for gastroretentive dosage forms: pharmacokinetics following continuous intragastric mode of administration in a rat model. Eur J Pharm Biopharm. 2008;69(1):238–246.
   PubMed Web of Science ®Google Scholar
• Friedman M, Hoffman A, Izgelov D, inventors; Yissum research development company of the Hebrew University of Jerusalem Ltd. Assignee. Floating drug delivery systems comprising cannabinoids patent WO2021137225. 2021.
   Google Scholar
• Navon N. The accordion pill: unique oral delivery to enhance pharmacokinetics and therapeutic benefit of challenging drugs. Ther Delivery. 2019;10(7):433–442.
   PubMedGoogle Scholar
• Navon N, Reinberg R, Yakovson Y, inventors; Intec Pharma Ltd., assignee. Oral gastroretentive formulations and uses thereof patent WO2018011798. 2018.
   Google Scholar